Full Name
Dr. Francesco Passamonti MD
Job Title
Division of Hematology, Department of Medicine and Surgery
Company/Affiliation
University of Milan
Speaker Bio
Prof. Francesco Passamonti is Professor of Hematology at the University of Insubria of Varese, Italy, and Head of the Division of Hematology of Varese. He obtained his medical degree from the University of Pavia, subsequently becoming a specialist in hematology. He worked as Assistant Professor of Hematology at the University of Pavia and as a hematologist at the Hematology of the I.R.C.C.S. Policlinico San Matteo, Pavia, Italy.
He is principal investigator for many clinical trials in hematologic malignancies; however, his main area of interest is in the Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs) polycythemia vera, essential thrombocythemia, and myelofibrosis. He collaborated on the definition of the molecular basis of MPNs and then designed translational studies to evaluate clinical implications of new molecular discoveries. He designed new prognostic models for essential thrombocythemia and primary and secondary myelofibrosis. He and his group perform many clinical trials on the development of targeted therapies in MPNs. After developing many trials with different JAK inhibitors, he is now interested in new combination trials working on phase 1b trials with ruxolitinib (JAK1/JAK2 inhibitor) and panobinostat (histone deacetylase inhibitor); ruxolitinib and buparlisib (Pi3K inhibitor); and ruxolitinib and sonidegib (hedgehog inhibitor). He participated as a panelist in the definitions of diagnostic criteria, response to treatments, and guidelines for treatment decision. He is a member of the board of the International Working Group on Myeloproliferative Research and Treatment, as well as the European LeukemiaNet Work Package 9 for MPN and the Working Party for MPN of GIMEMA. Prof. Passamonti is a member of several hematology societies and the Editorial Board of the American Journal of Hematology and is an invited speaker to several international meetings. He has authored and coauthored more than 220 articles on MPN and other hematological malignancies, reaching an h-index of 61 (Scopus, Sept 2019) or 78 (Google Scholar, Sept 2019).
He is principal investigator for many clinical trials in hematologic malignancies; however, his main area of interest is in the Philadelphia chromosome–negative myeloproliferative neoplasms (MPNs) polycythemia vera, essential thrombocythemia, and myelofibrosis. He collaborated on the definition of the molecular basis of MPNs and then designed translational studies to evaluate clinical implications of new molecular discoveries. He designed new prognostic models for essential thrombocythemia and primary and secondary myelofibrosis. He and his group perform many clinical trials on the development of targeted therapies in MPNs. After developing many trials with different JAK inhibitors, he is now interested in new combination trials working on phase 1b trials with ruxolitinib (JAK1/JAK2 inhibitor) and panobinostat (histone deacetylase inhibitor); ruxolitinib and buparlisib (Pi3K inhibitor); and ruxolitinib and sonidegib (hedgehog inhibitor). He participated as a panelist in the definitions of diagnostic criteria, response to treatments, and guidelines for treatment decision. He is a member of the board of the International Working Group on Myeloproliferative Research and Treatment, as well as the European LeukemiaNet Work Package 9 for MPN and the Working Party for MPN of GIMEMA. Prof. Passamonti is a member of several hematology societies and the Editorial Board of the American Journal of Hematology and is an invited speaker to several international meetings. He has authored and coauthored more than 220 articles on MPN and other hematological malignancies, reaching an h-index of 61 (Scopus, Sept 2019) or 78 (Google Scholar, Sept 2019).
Speaking At
